MeiraGTx

Yahoo Finance • 27 days ago

MeiraGTx CFO Giroux sells $204k in shares

Richard Giroux, Chief Financial Officer and Chief Operating Officer of MeiraGTx Holdings PLC (NASDAQ:MGTX), sold 24,000 ordinary shares of the company on July 22, 2025, according to a recent SEC filing. The shares were sold at a weighted... Full story

Yahoo Finance • last month

Meiragtx CEO Forbes sells $378k in shares

Alexandria Forbes, President and CEO of MeiraGTx Holdings PLC (NASDAQ:MGTX), sold 47,500 ordinary shares of the company on July 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a... Full story

Yahoo Finance • 3 months ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

LONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the Company will exhibit four poster presentations at the Amer... Full story

Yahoo Finance • 5 months ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process

- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV... Full story

Yahoo Finance • 6 months ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved visual acuity, functional vision, and... Full story

Yahoo Finance • 7 months ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings Plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the U.S. Food and Drug Administration (FDA) has granted the C... Full story

Yahoo Finance • 2 years ago

The past three years for MeiraGTx Holdings (NASDAQ:MGTX) investors has not been profitable

The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the last three years have been particularly tough on longer term MeiraGTx Holdings plc (NASDAQ:MGTX) shareholders. Unfortunately, they hav... Full story

Yahoo Finance • 2 years ago

MeiraGTx to Participate in Upcoming Investor Conferences

LONDON and NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Office... Full story

Yahoo Finance • 2 years ago

MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress

MeiraGTx Holdings PLC (NASDAQ:MGTX) announces Q3 2023 financial results with a net loss of $44.3 million. Sanofi's strategic investment of $30 million in MGTX shares and a right of first negotiation for gene regulation technology. Company'... Full story

Yahoo Finance • 2 years ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

- Received strategic investment from Sanofi purchasing $30 million of ordinary shares of the Company at a price of $7.50 per share in October 2023 - Announced a right of first negotiation (ROFN) with Sanofi for the use of MeiraGTx’s Ribos... Full story

Yahoo Finance • 2 years ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Sanofi to purchase $30 million of ordinary shares of the Company at a price of $7.50 per share Sanofi to receive a right of first negotiation (ROFN) for the use of MeiraGTx’s Riboswitch gene regulation technology for certain Immunology an... Full story

Yahoo Finance • 2 years ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

LONDON and NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit eight posters and deliver one oral presen... Full story

Yahoo Finance • 2 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatm... Full story

Yahoo Finance • 2 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27, 2023

LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on... Full story

Yahoo Finance • 2 years ago

MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting

LONDON and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will exhibit nine poster presentations at the American... Full story

Yahoo Finance • 2 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

Raised approximately $60 million in a private placement in May 2023 with investors consisting of several of the Company’s top shareholders On track for BLA submission of botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the trea... Full story

Yahoo Finance • 2 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shar... Full story

Yahoo Finance • 2 years ago

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2 signaling pathway to accelerate a series of cli... Full story

Yahoo Finance • 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

-   Announced positive clinical data from AQUAx AAV-hAQP1 Phase 1 trial for treatment of Grade 2/3Radiation-Induced Xerostomia in December 2022 -   Announced positive top-line data from the MGT009 Phase 1/2 clinical study demonstrating sa... Full story

Yahoo Finance • 3 years ago

MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.

-- Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) --Now Dosing Patients in Phase 1 Trial Evaluating AAV-GAD Gene Therapy for Parkin... Full story